Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics of 874 lung cancer patients treated with paclitaxel-based chemotherapy

From: Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study

Description of patients who received taxane-based chemotherapy
  Total (N = 874)
Age at Diagnosis  
 Mean (SD) 61.8 (10.4)
 Median (range) 63.0 (34.0-86.0)
Gender  
 Female 392 (44.9%)
 Male 482 (55.1%)
Cigarette smoking status  
 Never smokers 158 (18.1%)
 Former smokers 428 (49%)
 Current smokers 273 (31.2%)
 Some smokers 15 (1.7%)
Stage  
 SCLC  
 Limited 37 (4.2%)
 Extensive 39 (4.5%)
 NSCLC  
 Stage I and II 153 (17.5%)
 Stage III 328 (37.5%)
 Stage IV 317 (36.3%)
Histologic cell type  
 Adenocarcinoma/bronchioloalveolar carcinoma 465 (53.2%)
 Squamous cell carcinoma 162 (18.5%)
 Small cell carcinoma 76 (8.5%)
 Large cell carcinoma 28 (3.2%)
 Mixed and unspecified NSCLC 131 (15.0%)
 Others 12 (1.4%)
Tumor differentiation grade  
 Well differentiated 76 (8.7%)
 Moderately differentiated 332 (38.0%)
 Poor/undifferentiated 395 (45.2%)
 Nongradable or unknown 71 (8.1%)
Surgery, chemotherapy, radiation  
 Chemotherapy 238 (27.2%)
 Surgery & chemotherapy 157 (18%)
 Radiation & chemotherapy 311 (35.6%)
 Surgery & radiation & chemotherapy 168 (19.2%)
  1. Stage for NSCLC is described on the basis of the tumor-node-metastasis classification. The small cell lung cancer stage is described as suggested by the American Cancer Society as either “Extensive” or “Limited.” Abbreviations: SCLC, small cell lung cancer, NSCLC, non-small cell lung cancer.